The Philadelphia Business Journal (Free subscription) | 11/30/2009
Inovio Biomedical Corp. said Monday its drug-development partner Tripep completed a phase-I clinical study of its hepatitis C DNA vaccine.
Medical News Today (Free subscription) | yesterday
Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that its partner Tripep AB of Sweden has completed its phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine delivered using Inovio's electroporation technology. The study established the safety and tolerability of this therapy, with vaccine-induced immune...
Medical News Today (Free subscription) | yesterday
Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that its partner Tripep AB of Sweden has completed its phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine delivered using Inovio's electroporation technology. The study established the safety and tolerability of this therapy, with vaccine-induced immune...
Business Wire (Free subscription) | 11/30/2009
SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that its partner Tripep AB of Sweden has completed its phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine delivered using Inovio’s electroporation technology. The study established the safety and tolerability of this therapy,...
The Medical Quack (Free subscription) | 11/29/2009
... cells. Some of the other companies working in this direction include Celldex Therapeutics , Inovio Biomedical and MannKind Corp. The full article has details on these companies and a few more. This treatment program certainly sounds to have some real value to patients for sure in being either a potential replacement or enhancement to work with current chemotherapy processes. BD Despite the...
